CAS: 698-63-5; 5-Nitrofuran-2-Carbaldehyde

该化合物是一种有机化合物,其特征是,其柔性环结构被硝化物组和甲酰胺功能组所取代,是一种黄黄色或褐色液体或固体,其形态和纯度取决于其形态和纯度;该化合物以其反应性而著称,特别是由于硝化物组的存在而导致的电活性替代反应,它增加了呋喃环的电子缺乏. 5-硝化硫在乙醇和乙醚等有机溶剂中溶解,但水溶性有限,主要用于有机合成,并作为生产各种药品和农用化学品的一种中间体.此外,该化合物具有抗微生物特性,使其在医药化学中具有意义.安全考虑包括其潜在毒性以及需要适当处理和储存以避免接触.

结构式图片

相似化合物

645-12-5 1874-23-3 2493-04-1

欧盟法规

REACH注册ECHA物质C&L通报REACH预注册

上下游产品

(5-nitrofuran-2-yl)methanol 2-(iodomethyl)-5-nitrofuran chloroform 5-nitro-2-furfuraldehyde diacetate 5-nitro-2-acetylfuran furazolidone 3-(5-nitro-furfurylidenamino)-thiazolidin-2-one -2-imidazolidinon1-(5-Nitrofurfuryliden)amino-2-imidazolidinon

合成工艺路线路线简述

    糠醛置于硫酸,硝酸,乙酸酐体系中,用 水 作为反应溶剂,化学反应 1.08H,反应生成 5-硝基糠醛
    参考文献:基于bnim和radamide支架的葡萄糖调节蛋白94选择性抑制剂的开发.
    标题:基于bnim和radamide支架的葡萄糖调节蛋白94选择性抑制剂的开发.
    摘要:葡萄糖调节蛋白94(grp94)是分子伴侣蛋白的热休克蛋白90 Kda(hsp90)家族的内质网居民.grp94与许多参与细胞黏附和信号传导的蛋白质相关,包括整联蛋白,Toll样受体,免疫球蛋白和突变型myocilin.grp94被认为是包括青光眼,癌症转移和多发性骨髓瘤在内的多个治疗领域的靶标.虽然与其他hsp90同工型具有85%的相同性,但grp94的n末端atp结合位点具有一个独特的疏水性口袋,该口袋用于设计同工型选择性抑制剂.合并顺式-酰胺生物甾体进入radamide支架导致了最初的grp94选择性抑制剂bnim的开发.现在已经对bnim的芳基侧链进行了结构-活性关系研究,从而得到了改进的类似物,对grp94表现出了更好的效价和选择性.与bnim相比,这些类似物在转移模型中还表现出优异的抗迁移活性,并且在青光眼模型中还表现出增强的突变型肌球蛋白降解.
    DOI:10.1021/acs.Jmedchem.6B00085

    海关参考信息

    专利信息


    专利号:US-6251689-B1
    优先权日:1998-05-14
    标 题:Methods for the solid phase synthesis of combinatorial libraries of benzimidazoles benzoxazoles benzothiazoles and derivatives thereof
    发明人:LABORDE EDGARDO; MATSUMOTO YUKIHARU
    权利人:TELIK INC
    摘要:The present invention provides an efficient and versatile method for the synthesis and screening of combinatorial libraries of benzimidazoles, benzoxazoles, benzothiazoles, and derivatives thereof. In order to expedite the synthesis of large arrays of compounds possessing these core structures, a general methodology for solid phase synthesis of these derivatives is provided. Arrays of benzimidazoles, benzoxazoles, benzothiazoles, and derivatives thereof useful as peptidomimetics and for the identification of agents having antifungal, antiviral, antimicrobial, anticoagulant, and antiulcer activity, or use in the treatment of inflammation, hypertension, cancer, and other conditions can be prepared by this method.

    专利号:US-9284306-B2
    优先权日:2012-05-11
    标题 :(R)-Nifuratel, its use for the treatment of infections and synthesis of (R) and (S)-Nifuratel
    发明人:GAGLIARDI STEFANIA; CONSONNI ALESSANDRA; MAILLAND FEDERICO; BULGHERONI ANNA
    权利人:POLICHEM SA
    摘要:(R)-Nifuratel is disclosed together with its use as bactericide and bacteriostatic agent as well as the pharmaceutical compositions containing the same; (R)-nifuratel has been surprisingly found to possess a better antimicrobial profile than either nifuratel racemate or (S)-nifuratel. A new procedure for the synthesis of both (R)-Nifuratel and (S)-Nifuratel is also disclosed.

    专利号:US-6121054-A
    优先权日:1997-11-19
    标 题 :Method for separation of liquid and solid phases for solid phase organic syntheses
    发明人:LEBL MICHAL
    权利人:TREGA BIOSCIENCES INC
    摘要:A simple, efficient apparatus and method for separation of solid and liquid phases useful in methods of high-throughput combinatorial organic synthesis of large libraries or megaarrays of organic compounds is disclosed. The apparatus and method are useful, whether as part of an automated, robotic or manual system for combinatorial organic synthesis. In a preferred embodiment, an apparatus and method of removal of liquid phase from solid phase compatible with microtiter plate type array(s) of reaction vessels is disclosed.

    专利号:US-9949970-B2
    优先权日:2010-09-14
    标题 :Synthesis of new benzothiazole derivatives as potential anti-tubercular agents
    发明人:KAMAL AHMED; SHETTI RAJESH VCRNC; SWAPNA PONNAMPALLI; AZEEZA SHAIK; REDDY A MALLA; KHAN INSHAD ALI; ABDULLAH SHEIKH TASDUQ; SHARMA SANDEEP; KALIA NITIN PAL
    权利人:COUNCIL SCIENT IND RES
    摘要:Disclosed are compounds of general formula A useful as potential anti-tubercular agents. The general formula A is

    专利号:EP-0043598-B1
    优先权日:1980-07-09
    标 题:Process for the transformation of furfural or 5-nitro-furfural into furonitrile or 5-nitro-furonitrile
    摘要:1. Process for the transformation of furfural or 5-nitro-furfural into furonitrile or 5-nitro-furonitrile, in which furfural or 5-nitro-furfural is brought into contact with a hydroxylamine salt, characterized in that the synthesis of furonitrile or 5-nitro-furonitrile is achieved in a single step, by bringing the furfural or 5-nitro-furfural into contact with the hydroxylamine salt in N-methyl pyrrolidone (N.M.P.), the mixed substances being taken to a temperature of between 120 degreees C and 165 degrees C.

    专利号:US-9220714-B2
    优先权日:2006-03-16
    标 题 :Nitrofuran compounds for the treatment of cancer and angiogenesis
    发明人:SAULNIER SHOLLER GISELLE L; SWAMY NARASIMHA; KALKUNTE STAYAN; SINGH RAKESH K; BRARD LAURENT; KIM KYU KWANG
    权利人:WOMEN AND INFANTS HOSPITAL OF RHODE ISLAND; UNIV BROWN; WOMEN AND INFANTS HOSPITAL RHODE ISLAND
    摘要:The invention is directed to the synthesis and use of nitrofuran compounds, especially Nifurtimox, as medicaments to treat cancer, especially neuroblastoma, and to inhibit angiogenesis. The invention also provides compositions, unit dosage forms, and kits comprising the compounds.
    南通增德瑞生物科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.zdrbio.com/
    电话: 0513-87582998👤
    📞南通增德瑞生物科技有限公司 ⚠️参考联系方式

    销售电话:0513-87582998
    邮箱:sales01@zdrbio.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    杭州氟药药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.fluoropharm.cn
    企业联系电话:0571-85586753;13336034509(微信同号)👤
    📞杭州氟药药业有限公司 ⚠️参考联系方式
    联系人:张经理
    电话:0571-85586753;13336034509(微信同号)
    手机:13336034509
    传真:询价请加QQ 2818889690 或发邮件
    邮箱:sales@fluoropharm.com
    通信地址: 浙江省杭州市滨江区西兴街道江陵路88号
    邮编: 310053
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:浙江省杭州市滨江区西兴街道江陵路88号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献

    [参考文献]: A Cisak, Et Al. Reactivity Of 5-Nitro-2-Furaldehyde In Alkaline And Acidic Solutions. Acta Pol Pharm. 2001 Nov-Dec;58(6):427-34.
    [参考文献]: Jun Li, Et Al. Broad Specificity Indirect Competitive Immunoassay For Determination Of Nitrofurans In Animal Feeds. Anal Chim Acta. 2010 Sep 23;678(1):1-6.
    [参考文献]: M Arivazhagan, Et Al. Conformational Stability, Vibrational Spectra, Molecular Structure, Nbo And Homo-Lumo Analysis Of 5-Nitro-2-Furaldehyde Oxime Based On Dft Calculations. Spectrochim Acta A Mol Biomol Spectrosc. 2013 Mar:104:14-25.
    [参考文献]: M I Walash, Et Al. Stability-Indicating First-Derivative Spectrophotometric Determination Of Furazolidone. Acta Pharm Hung. 1994 Jan;64(1):5-8.
    [参考文献]: Nilesh R Tawari, Et Al. Design, Synthesis, And Biological Evaluation Of 4-(5-Nitrofuran-2-Yl)Prop-2-En-1-One Derivatives As Potent Antitubercular Agents. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6175-8.

    合成参考文献


    摘要:Kimura, T., Science of Synthesis Knowledge Updates, (2016) 2, 435.
    摘要:GENE-TOX Program: Current Status of Bioassay in Genetic Toxicology. U.S. Environmental Protection Agency, Washington, DC. Office of Toxic Substances and Pesticides. (For program information, contact Environmental Mutagen Information Center, Oak Ridge National Laboratory, Post Office Box Y, Oak Ridge, Tennessee 37830. Telephone (615) 574-7871)
    摘要:KONICEK J ET AL; STUD PNEUMOL PHTISEOL CECH 37(7) 452 (1977)
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知